Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Gilead turns down chance to build on Assembly’s phase 1-stage HBV antiviral

Gilead turns down chance to build on Assembly’s phase 1-stage HBV antiviral

  • March 20, 2026

Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner on other assets.

Leave A Comment

Fields (*) Mark are Required